Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemotherapy: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature.
CONCLUSION: Our case highlights the possibility of combining chemotherapy with PD-1 and VEGF/VEGFR2 inhibitors for the treatment of cholangiocarcinoma patients. This combination may herald new hope for patients who run out of regimens. PMID: 33390149 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 6, 2021 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anti-EGFR-mAb and 5-Fluorouracil conjugated Polymeric Nanoparticle for Colorectal Cancer.
CONCLUSIONS: From the outcomes of various experiments, it was concluded that Anti-EGFR-5-FU-PLGA-PEG-NP has biphasic drug release kinetics, higher cellular uptake & higher cytotoxicity. Therefore, Anti-EGFR-5-FU-PLGA-PEG-NP holds excellent potential for drug delivery to EGFR positive colorectal cancer cells. PMID: 33349222 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 24, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
CONCLUSION: In parallel to current patents, NGS could be applied as a novel strategy in the managing of NSCLC patients with LM. PMID: 33245275 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 28, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Anti-Proliferative Effect of a Newly-Produced Anti-PSCA-Peptide Antibody by Multiple Bioinformatics Tools, on Prostate Cancer Cells.
Authors: Chizari M, Kheshti SF, Taeb J, Farajollahi MM, Mohsenzadegan M Abstract BACKGROUND: Prostate Stem Cell Antigen (PSCA) is a small cell surface protein, overexpressed in 90% of prostate cancers. Determination of epitopes that elicit an appropriate response to the antibody generation is vital for diagnostic and immunotherapeutic purposes for prostate cancer treatment. Presently, bioinformatics B-cell prediction tools can predict the location of epitopes, which is uncomplicated, faster, and more cost-effective than experimental methods. OBJECTIVE: We aimed to predict a novel linear peptide for Prostate Ste...
Source: Recent Patents on Anti-Cancer Drug Discovery - November 14, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer.
CONCLUSION: Accumulating evidences suggest that curcumin has potentiality to inhibit cancer growth, induced apoptosis and modulate various cell signalling pathways molecules. Well-designed clinical trials of curcumin based on human subjects are still needed to establish the bioavailability, mechanism of action, efficacy and safe dose in the management of various cancers. PMID: 33143616 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 6, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Terpenes with Antitumor Activity: A Patent Review.
CONCLUSION: Natural products are an important source of compounds for use in the fight against cancer that can act synergistically, and help in the treatment of cancer. PMID: 33138764 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 4, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

In Vitro and In Vivo Evaluation of Novel DTX-Loaded Multifunctional Heparin-Based Polymeric Micelles Targeting Folate Receptors and Endosomes.
CONCLUSION: Our results indicated that DTX-loaded multifunctional heparin-based micelles with desirable antitumor activity and low toxicity possess great potential as a targeted drug delivery system in the treatment of cancer. PMID: 33023456 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 9, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anticancer Effect of Melatonin via Downregulation of Delta-Like Ligand 4 in Estrogen-Responsive Breast Cancer Cells.
CONCLUSION: It can be concluded that melatonin treatment attenuated DLL4 expression only in estrogen-responsive breast cancer cells and is able to induce apoptosis in breast cancer cells. PMID: 32990541 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugate in Oncohematology.
CONCLUSION: Immunotherapy and immuno-chemotherapy have improved the outcome of the patients with malignant hemopathies through a targeted, personalized therapy, with reduced systemic toxicity, which in some cases can even induce deep complete remissions, including minimal residual disease negativity. PMID: 32981510 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 29, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent Advances in Development of Selective Mcl-1 Inhibitors for Treatment of Cancer (2017-Present).
CONCLUSION: For most of the compounds in these patents, analyses of the binding affinity to Mcl-1 and studies in multiple cell lines were conducted, wherein some compounds were tested in preclinical cancer models or were included in other biological studies. Some compounds showed promising results and potential for further study. PMID: 32938354 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 19, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
CONCLUSION: PI3K/mTOR signalling blockers have evolved as promising anticancer agents by interfering breast cancer development and progression at various stages. Natural products and bioactive components are emerging as novel inhibitors of PI3K signalling and more research in this area may yield numerous drug candidates. PMID: 32914720 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 12, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

RNA Splicing: Basic Aspects Underlie Antitumor Targeting.
CONCLUSION: Pharmacological modulation of RNA splicing sets stage for treatment approaches in situations where mRNA splicing is a clinically meaningful mechanism of the disease. PMID: 32900350 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 11, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
Conclusion: EGFR plays a role in transmembrane signal transduction. The Nbs, especially anti-EGFR-Nbs have shown effectiveness in the diagnosis and treatment of solid tumours. How to increase the affinity of Nb and reduce its immunogenicity remains a great challenges. PMID: 32885759 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 6, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Dichloromethane Fraction of Vernonia cinerea Impart Pro-Apoptotic, Genotoxic, Cell Cycle Arrest, and Drug Efflux Inhibitory Effects in Human Adenocarcinoma Cells.
Conclusion: The bioactivity guided fractionation of VC revealed that the specific 'sesquiterpenoids enriched fraction' (VC-DM) imparted cytotoxicity in human adenocarcinoma cells with fewer effects on normal cells. Mechanistic studies have shown that VC-DM induced apoptosis, DNA damage, genotoxicity, cell cycle arrest (G2/M), inhibited the functional activity of MDR transporters (ABCB1 and ABCG2), and produced 'synergistic cytotoxic effects' (combinatorial treatments with anticancer drugs) in human adenocarcinoma cells. Taken together, the findings of this study emphasize and validates VC-DM as a promising 'anticancer agen...
Source: Recent Patents on Anti-Cancer Drug Discovery - August 26, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer.
CONCLUSION: JPJDF and fluoropyrimidine has synergistic effect in the maintenance treatment of mCRC. PMID: 32679021 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 19, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Developments in the Application of 1,2,3-Triazoles in Cancer Treatment.
CONCLUSION: Triazole-containing molecules with anticancer activity are being widely synthesized and extensively tested. They vary significantly in terms of both structure and mechanism of action. The methods for their preparation and administration are well established and with proven reproducibility. These facts suggest that triazoles may play an important role in the discovery of novel antiproliferative medications with improved effectiveness and safety profile. PMID: 32679022 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 19, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Cancer Stem Cells and their Management in Cancer Therapy.
CONCLUSIONS: The significant roles of cell therapy may include an auto-transplant with high-dose treatment, an improvement of the immune function, the creation of chimeric antigen receptor T cells, and the recruitment of NK cellbased immunotherapy. PMID: 32660407 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 16, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anticancer Potential of Aguerin B, a Sesquiterpene Lactone Isolated from Centaurea behen in Metastatic Breast Cancer Cells.
CONCLUSION: Taken together, this study demonstrated that aguerin B possessed potential anti-metastatic effect, suggesting that it may consider as a potential multi target bio compound for treatment of breast metastatic carcinoma. PMID: 32660408 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 16, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent Patents on Anticancer Potential of Helenalin.
CONCLUSION: The promising anticancer potential of helenalin in various preclinical studies may open new avenues for therapeutic interventions in different tumors. Thus clinical trials validating its tumor suppressing and chemopreventive activities particularly in conjunction with standard therapies, are immediately required. PMID: 32614752 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 4, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent Patents on the Development of c-Met Kinase Inhibitors.
CONCLUSION: c-Met kinase inhibitors have emerged as exciting new drug classes in the treatment of all kinds of cancers, especially the Non-Small Cell Lung Cancer (NSCLC) with tumor resistance. More attention should be paid on the natural product to find novel c-Met kinase inhibitors. PMID: 32603284 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Modulation of MicroRNAs by Euphorbia microsciadia Boiss in MDA-MB-231: New Possibilities in Breast Cancer Therapy.
CONCLUSION: E. microsciadia could modulate some miRNAs involved in cell cycle arrest and apoptosis in MDA-MB-231 cell line. Accordingly, targeting miRNAs by E. microsciadia can open some newer avenues for breast cancer therapy. PMID: 32603285 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: Recent Patents Review.
CONCLUSION: Focus on most important factors involved in UPS and autophagy such as ATG, 20s proteasome and mTOR, ATG8, FIP200, and TIGAR can be considered in drug therapy for controlling or activating autophagy. PMID: 32603286 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature.
CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 4, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Increased NID1 Expression among Breast Cancer Lung Metastatic Women; A Comparative Analysis between Naive and Treated Cases.
CONCLUSIONS: The increased expression of NID1 in early to advanced naive as compared to the treated groups with Lung metastasis makes it a promising marker which has pro-metastatic role in Breast cancer. PMID: 32116201 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 4, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Feasibility of Repurposing Clioquinol for Cancer Therapy.
CONCLUSION: Clioquinol exhibits anti-cancer activities in many cancer types preclinically. Low therapeutic efficacy in a clinical trial has prompted new studies that aim in discovering more effective clioquinol-based cancer therapies. PMID: 32106803 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Molecular Docking of Flavonoids Isolated from Daucus carota as a Dual Inhibitor of MDM2 and MDMX.
CONCLUSION: Thus the compound7 can be used for the revival of p53 signaling pathway function however, intensive in vitro and in vivo experiments are required to prove the in silico analysis. PMID: 32101134 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 28, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
CONCLUSION: Selectively targeting HDAC6 over other subtypes represents two fold advantages: maximize the pharmacological effects and minimize the side effects seen in pan-HDAC inhibitors. Many small molecule selective HDAC6 inhibitors have advanced to clinical studies in recent years. We anticipate the approval of selective HDAC6 inhibitors as therapeutic agents in near future. PMID: 32065106 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 20, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

SOX4 Serves an Oncogenic Role in the Tumourigenesis of Human Breast Adenocarcinoma by Promoting Cell Proliferation, Migration and Inhibiting Apoptosis.
In this study, we explored the effects of sex-determining region Y-box 4 (SOX4) protein on the proliferation, migration, apoptosis and tumourigenesis of breast adenocarcinoma and its possible mechanisms. METHODS: The SOX4 overexpression or knockdown michigan cancer foundation-7 (MCF-7) cell lines were established. Among the SOX4 overexpression or MCF-7 knockdown cell lines, the proliferation, migration ability and apoptosis rate were detected. The expression levels of apoptosis-related proteins (Bax and Cleaved caspase-3) were analysed using Western blot. The effect of SOX4 on tumourigenesis was analysed using the clon...
Source: Recent Patents on Anti-Cancer Drug Discovery - February 14, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years.
Conclusion: Many newly found alkaloids displayed potent anticancer activity both in vitro and in vivo, and some of the anticancer alkaloids acted as protein kinase inhibitors or CDK inhibitors possess potential for developing as novel anticancer agents. PMID: 32003702 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Toward a Personalized Use of Paclitaxel.
Authors: Russo GL PMID: 31920185 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 12, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Expression of B Cell Translocation Gene 1 Protein in Colon Carcinoma and its Clinical Significance.
In this study, we investigated the expression of BTG1 protein in colon cancer, and its association with clinicopathology and prognosis. METHODS: The tumor specimens from 59 patients with colon cancer who had undergone radical colectomy were selected as the observation group. Para-carcinoma tissues from the same patients were selected as the control group. The expression of BTG1 mRNA and protein in the specimen of two groups were analyzed by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western blot. According to the immunohistochemical results, the patients were divided into BTG1-negative and BTG1-posi...
Source: Recent Patents on Anti-Cancer Drug Discovery - January 11, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Lentiviral-Mediated Beclin-1 Overexpression Inhibits Cell Proliferation and Induces Autophagy of Human Esophageal Carcinoma Eca109 Cell Xenograft in Nude Mice.
CONCLUSION: BECLIN-1 can induce autophagy in esophageal carcinoma Eca109 cells, and it can significantly inhibit the growth of esophageal carcinoma. PMID: 31823702 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 13, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer Drugs.
Authors: Baldo P PMID: 31778105 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 30, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks.
CONCLUSION: This mini-review will explain the present research status of Apigenin and will further throw some light on how Apigenin performs its anti-cancerous actions by interfering with the key cell-signaling pathways. PMID: 31746310 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

MDM2-p53 Interaction Inhibitors: Current State of Art and Updated Patent Review (2010-present).
CONCLUSION: Novel MDM2 inhibitors thanks to higher potency and better ADME properties have shown effectiveness in preclinical and clinical development however the final improvement of therapeutic potential for MDM2 inhibitors might depend on the useful combination therapy and exploring new cancer and non-cancer indications. PMID: 31642413 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 24, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Chimeric Antigen Receptor-Engineered T-Cells - a New Way and Era for Lymphoma Treatment.
CONCLUSION: CAR T-cell therapy significantly improved the outcome of patients with relapsed or refractory diffuse large B-cell lymphoma. The advances in CAR T-cells production technology will improve the results and enable the expansion of this new immunotherapy. PMID: 31642414 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 24, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Mechanism of a Novel Camptothecin-Deoxycholic Acid Derivate Induced Apoptosis Against Human Liver Cancer HepG2 Cells and Human Colon Cancer HCT116 Cells.
Conclusion: These findings suggested that the apoptotis in both cell lines induced by G2 in both cell lines was related to both the extrinsic and intrinsic pathways. PMID: 31644410 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 24, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Association between hTERT Polymorphisms and Female Papillary Thyroid Carcinoma.
CONCLUSION: Our finding suggests that hTERT polymorphisms rs10069690 and rs2736100 are associated with increased risk for PTC in Chinese female population and rs2736100 may be related to age. Consistent with US20170360914 and US20170232075, they are expected to be potential molecular target for anti-cancer therapy. PMID: 31538903 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Tissue Distribution and Systemic Toxicity Evaluation of Raloxifene Targeted Polymeric Micelles of Poly (Styrene-Maleic Acid)-Poly (Amide-Ether-Ester-Imide)-Poly (Ethylene Glycol) Loaded With Docetaxel in Breast Cancer Bearing Mice.
CONCLUSION: The results indicate that RA-conjugated polymeric micelles may be a strong and effective drug delivery system for DTX therapy and uptake of drug into tumor cells, and overcome the disadvantages and side effects of conventional DTX. PMID: 31538904 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

HMGA and Cancer: A Review on Patent Literatures.
CONCLUSION: Powerful strategies able to selectively interfere with HMGA expression and function could represent a helpful approach in the development of new anti-cancer therapies. PMID: 31538905 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
CONCLUSION: It is essential to investigate the safety profile of the recent anticancer drugs for advanced thyroid cancer to allow health professionals to make the best choice for each patient by evaluating the risk/benefit assessment. PMID: 31362663 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - August 1, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
CONCLUSION: The new oncological therapies against melanoma are based on increasingly specific biological and immunological targets. For this reason, the potential toxicities that are expected from patients would be less relevant than the systemic "classical" chemotherapy. However, the new therapies are not free from the risk of causing adverse reactions, some of which must be managed promptly and appropriately; moreover the multiplicity of the metabolic pathways exposes the new target therapies to relevant potential interactions. This review can help to understand how important it is not to underestimate ...
Source: Recent Patents on Anti-Cancer Drug Discovery - August 1, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer.
CONCLUSION: Currently, a consistent number of new drugs and combinations have been introduced for the treatment of patients with advanced-stage lung cancer. Safety data remain essential to better assess the long-term risk/benefit ratio of these valuable emerging therapies. The new patents' development could provide further significant improvements for lung cancer treatment. PMID: 31362665 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - August 1, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

A truncated Snail1 transcription factor alters expression of essential EMT markers and suppresses tumor cell migration in a human lung cancer cell line.
CONCLUSIONS: Transfection of A549 cells with CSnail1 alters expression of essential EMT markers and consequently suppresses tumor cell migration. These findings confirm capability of CSnail1 in EMT blocking and in parallel to current patents could be applied as a novel strategy in prevention of metastasis. PMID: 31131753 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 29, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Inhibitory effect of hydroxysafflower yellow B on the proliferation of human breast cancer MCF-7 cells.
CONCLUSION: These data demonstrate that HSYB arrests the MCF-7 cell cycle at the S phase and induces cell apoptosis. Patent US20170246228 indicates that HSYB can be potentially used for the prevention and treatment of human breast cancer. PMID: 31096897 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 19, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Repurposing Disulfiram as an Anti-Cancer Agent: Updated Review on Literature and Patents.
CONCLUSION: For years the FDA-approved, well-tolerated, inexpensive, orally-administered drug Disulfiram was used in the treatment of chronic alcoholism, but it has recently demonstrated anti-cancer effects in a range of solid and hematological malignancies. Its combination with clinically relevant copper concentrations might overcome the resistance of many anti-cancer drugs in vitro, in vivo, and in patients. PMID: 31084595 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 16, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK.
Conclusion: Tumor tissue concentration-time curves of CPT-11 and SN-38 can be determined via PBPK modeling. Rate constants of enzymes and transporters can be shown for healthy and tumor bearing individuals. The results will throw light on the effective concentration of active compound at its target tissue at the clinically applied IV dose. PMID: 30760193 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 16, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

From Antimicrobial to Anticancer Peptides: The Transformation of Peptides.
CONCLUSION: These findings may have important clinical implications for cancer treatment, especially in patients with conditions that are not currently treatable by other drugs, or that are resistant to existing cancer drugs. PMID: 30663573 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 23, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents.
CONCLUSION: The promising anti-cancer effects shown by TTs in several preclinical studies may open new opportunities of therapeutic interventions in different tumors. Thus, clinical trials aimed at confirming TTs chemopreventive and tumor-suppressing activity, particularly in combination with standard therapies, are urgently needed. PMID: 30652648 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
CONCLUSION: Powerful strategies able to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies. PMID: 30652649 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research